Sugi Predict

Sugi Predict / Compounds / SCHEMBL738457

SCHEMBL738457

SCHEMBL738457

Cc1c(C(=O)N(C)c2ccccc2)ccnc1Cl

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.56
▸ KMT2A Q03164 3/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ LMNA P02545 2/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ GPBAR1 Q8TDU6 3/20 0.44
▸ HTT P42858 1/20 0.42
▸ MAOB P27338 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ EGFR P00533 1/20 0.40
▸ ERBB2 P04626 1/20 0.40
▸ SIRT2 Q8IXJ6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12300200 0.82 POLB (0.64) POLBKMT2AKDM4ELMNAMEN1
SCHEMBL3058847 0.81 PDK1 (0.50) NPC1RAB9ASMN1; SMN2HTT
SCHEMBL581067 0.76 SMN1; SMN2 (0.55) KDM4ELMNARAB9AL3MBTL1SMN1; SMN2
SCHEMBL5446778 0.75 POLB (0.58) POLBKMT2AKDM4EMEN1HTT
Hydrochloric Acid SCHEMBL6524532 0.74 SMN1; SMN2 (0.53) KDM4ELMNARAB9AL3MBTL1SMN1; SMN2
SCHEMBL14490114 0.73 KMT2A (0.61) POLBKMT2AKDM4ELMNAMEN1
SCHEMBL9001638 0.73 POLB (0.75) POLBKMT2AKDM4ELMNAL3MBTL1
SCHEMBL8074384 0.73 KMT2A (0.59) POLBKMT2AKDM4ELMNAMEN1
SCHEMBL3455835 0.73 POLB (1.00) POLBKMT2AKDM4ELMNASMN1; SMN2
SCHEMBL18426272 0.72 NOTUM (0.48) POLBKMT2AKDM4EL3MBTL1GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113248492-B Heterocycle substituted nitrogen-containing six-membered heterocyclic derivative, preparation method and medical application thereof 上海海雁医药科技有限公司 2022-11-08 — — CN disclosed
EP-3470396-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2019-04-17 — — EP disclosed
EP-3470396-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2019-04-17 — — EP disclosed
EP-3165520-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme Inc (US) 2017-05-10 — — EP disclosed
EP-3165520-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme Inc (US) 2017-05-10 — — EP disclosed
US-20160332969-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2016-11-17 — — US disclosed
US-9376422-B2 Dihidropyridin-2-one benzamine compounds Epizyme, Inc. (US) 2016-06-28 — — US disclosed
EP-2697198-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2016-06-08 — — EP disclosed
EP-2697198-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2016-06-08 — — EP disclosed
US-20140142083-A1 Substituted Benzene Compounds Epizyme, Inc. (US) 2014-05-22 — — US disclosed
US-20070111989-A1 Novel diazabicyclononene derivatives and use ACTELION PHARMACEUTICALS LTD. (CH) 2007-05-17 — — US disclosed
US-20060258648-A1 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors ACTELION PHARMACEUTICALS, LTD. (CH) 2006-11-16 — — US disclosed
EP-1692133-A1 DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2006-08-23 — — EP disclosed
EP-1673341-A1 TETRAHYDROPYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2006-06-28 — — EP disclosed
WO-2006021403-A1 BICYCLONONENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-03-02 — — WO disclosed
WO-2006021402-A1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD. (CH) 2006-03-02 — — WO disclosed
EP-1622685-A1 9-AZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2006-02-08 — — EP disclosed
WO-2005054243-A1 DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2005-06-16 — — WO disclosed
WO-2005040120-A1 TETRAHYDROPYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2005-05-06 — — WO disclosed
WO-2004096366-A1 9-AZABICYCLO’3.3.1!NON-6-EE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2004-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111989-A1 Novel diazabicyclononene derivatives and use REN, ACE, AGTR1 POLB 2792/4885KMT2A 3009/4885KDM4E 1488/4885
US-20140142083-A1 Substituted Benzene Compounds CYP1B1, TP53, VHL POLB 912/4885KMT2A 1120/4885KDM4E 711/4885
US-20060258648-A1 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors REN, ACE, AGTR1 POLB 994/4885KMT2A 3580/4885KDM4E 1001/4885
US-20160332969-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL POLB 912/4885KMT2A 1120/4885KDM4E 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.